Saturday 17 October 2026
Export VRPX’s income statement to Excel — free account
Virpax Pharmaceuticals, Inc.
VRPX Healthcare Biotechnology
In the quarter to December 2024, EPS grew 153.6% and free cash flow grew 4.68%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow VRPX
| Older periods | Mar '24 | Jun '24 | Sep '24 | Dec '24 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.72 | 0.48 | 0.13 | 0.63 |
Net Debt/EBITDA |
0.57 | 0.54 | 0.01 | 0.45 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.40 | 0.48 | 2.23 | 0.85 | |
Interest Coverage |
— | (314.40) | (20.76) | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(165.16) | (20.78) | (23.99) | (16.87) | |
Cash per Share |
39.87 | 23.65 | 0.09 | 8.89 | |
Shareholders Equity per Share |
(25.93) | (35.33) | (11.01) | (5.37) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(25.93) | (35.33) | (11.01) | (5.37) | |
Free Cash Flow |
(7.73) | (1.64) | (4.47) | (2.87) | |
Working Capital |
(1.21) | (2.79) | (2.05) | (0.91) | |
Net Current Asset Value |
(1.21) | (2.79) | (2.05) | (0.91) | |
| Other line items | |||||
Quick Ratio |
0.43 | 0.35 | 0.01 | 0.61 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(165.16) | (20.78) | (23.99) | (16.87) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.57 | 2.27 | 1.94 | 2.08 | |
Average Assets |
10.81 | 9.27 | 6.67 | 5.59 | |
Average Common Equity |
6.99 | 4.76 | 2.23 | 0.51 |
Columns are period end dates